Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
Recruiting
Phase 4
Interventional Study
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Amyloidosis
Amyloid Cardiomyopathy
Transthyretin Amyloidosis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 150 (estimated)
- Sponsor
- Eidos Therapeutics, a BridgeBio company · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Key Inclusion Criteria:
* Participants aged 18 to 80
* Confirmed diagnosis of ATTR-CM requiring targeted therapy
* At screening: New York Heart Association (NYHA) Class I/II; estimated glomerular filtration rate (eGFR) ≥40 mL/min/1.73m2; left ventricular ejection fraction (LVEF) \>35%; left ventric…
Contacts